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Abstract
Introduction Left ventricular ejection fraction (LVEF)
≤35%, as current significant implantable cardioverterdefibrillator (ICD) indication for primary prevention of
sudden cardiac death (SCD) in heart failure (HF) patients,
has been widely recognised to be inefficient. Improvement
of patient selection for low LVEF (≤35%) is needed to
optimise deployment of ICD. Most of the existing prediction
models are not appropriate to identify ICD candidates at
high risk of SCD in HF patients with low LVEF. Compared
with traditional statistical analysis, machine learning (ML)
can employ computer algorithms to identify patterns in
large datasets, analyse rules automatically and build both
linear and non-linear models in order to make data-driven
predictions. This study is aimed to develop and validate
new models using ML to improve the prediction of SCD in
HF patients with low LVEF.
Methods and analysis We will conduct a
retroprospective, multicentre, observational registry
of Chinese HF patients with low LVEF. The HF patients
with LVEF ≤35% after optimised medication at least
3 months will be enrolled in this study. The primary
endpoints are all-cause death and SCD. The secondary
endpoints are malignant arrhythmia, sudden cardiac
arrest, cardiopulmonary resuscitation and rehospitalisation
due to HF. The baseline demographic, clinical, biological,
electrophysiological, social and psychological variables
will be collected. Both ML and traditional multivariable Cox
proportional hazards regression models will be developed
and compared in the prediction of SCD. Moreover, the ML
model will be validated in a prospective study.
Ethics and dissemination The study protocol has been
approved by the Ethics Committee of the First Affiliated
Hospital of Nanjing Medical University (2017-SR-06). All
results of this study will be published in international peerreviewed journals and presented at relevant conferences.
Trial registration number ChiCTR-POC-17011842; Preresults.

Strengths and limitations of this study
►► This study is the first multicentre registry study in

China, aimed to investigate the feasibility and accuracy of applying machine learning (ML) to predict
sudden cardiac death (SCD) in heart failure (HF)
patients with low left ventricular ejection fraction
(LVEF).
►► A broad range of outcomes, including SCD, all-cause
death, lethal arrhythmia, sudden cardiac arrest, cardiopulmonary resuscitation and rehospitalisation
due to HF, will be evaluated in this study, and the
corresponding prognostic models will be developed.
►► ML and the traditional multivariable Cox proportional
hazards regression model will be derived from the
same database and be compared.
►► HF patients with LVEF >35% will not be included
based on the design of this study, which will restrict
the application of the results of this study to the HF
with low LVEF.
►► It might be difficult to determine the endpoint of this
study sometimes for some patients, when dealing
with SCD, lethal arrhythmia and sudden cardiac arrest, especially when outside the hospital.

Introduction
Heart failure (HF) has become a major
public health problem with increased prevalence in both Asia and Western countries.
The prevalence of HF in Asia is 1.2%–6.7%
depending on the population studied.1 In
China, there are 4.2 million HF patients, and
500 000 new cases are being diagnosed each
year.1 Although the survival rate after HF
diagnosis has been increased due to improvement in medical therapy, the mortality of HF
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Furthermore, a noticeable decline in the rate of SCD for
HF patients with reduced LVEF has been observed, which
was consistent with the cumulative benefit of optimising
medication including ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB), beta-blocker and mineralocorticoid receptor antagonist (MRA).13 Therefore, it is
imperative to update the criterion for ICD implantation.
Over the last decade, lots of multivariate prognostic
models derived for chronic HF patients have been
proposed (table 1).14–25 However, these models are not
appropriate to identify ICD candidates at high risk of
SCD in HF patients with low LVEF. Most above prognostic
scores were developed form trial databases, and the
subjects included various types of HF. There is no specific
study for the prognosis of low LVEF population. Additionally, although all the scores are ‘not parsimonious’,
some critical factors are not incorporated into the prognostic models, for example, medications are contained in
Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE),17 Meta-Analysis Global Group
in Chronic Heart Failure (MAGGIC)21 and Cardiac and
Comorbid Conditions HF (3C-HF).23 Optimised medication was not required as inclusion criteria in all 12 studies.
Furthermore, the most above prognostic models are not
able to predict SCD risk. In recent years, the advances
in strain echocardiography,26 27 cardiac magnetic resonance26 27 and cardiac radionuclide imaging28 29 have
provided essential insights into the mechanisms of

Table 1 The risk model for HF in the literature
Author
Agostoni

14

Database

Year

MECKI

2012

Variables (n)

Patients (n)

Barlera15

GISSI-HF

2013

14

6975

Cardiovascular death; urgent cardiac
transplant
All-cause mortality

Collier16

EMPHASIS-HF

2013

10

2737

All-cause mortality

I-PRESERVE

2011

12

4128

All-cause mortality

Komajda

17

18

6

2716

Endpoints

SHFM

2006

14

1125

Survival

O'Connor19

HF-ACTION

2012

4

2331

All-cause mortality

Pocock20

CHARM

2006

21

7599

All-cause mortality

Pocock21

MAGGIC

2012

13

39 372

All-cause mortality

Senni22

CVM-HF

2006

13

292

All-cause mortality

Senni

3C-HF

2013

11

2016

Vazquez24

MUSIC

2009

10

992

Uszko-Lencer25

BARDICHE-index

2017

8

1811

Levy

23

All-cause mortality; urgent heart
transplant (1 year)
All-cause mortality; cardiac mortality;
pump failure death, sudden death
All-cause mortality; all-cause
hospitalisation; CHF-related
hospitalisation

BARDICHE, Body mass index (B), Age (A), Resting systolic blood pressure (R), Dyspnea (D), N-terminal pro brain natriuretic peptide (NTproBNP) (I), Cockroft-Gault equation to estimate glomerular filtration rate (C), resting Heart rate (H), and Exercise performance using 6-min
walk test (E); CHARM, the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidityj; CVM-HF, CardioVascular
Medicine Heart Failure index; EMPHASIS-HF, the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure trial; GISSIHF, Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart failure Trial; HF, heart failure; HF-ACTION, A Controlled
Trial Investigating Outcomes of Exercise TraiNing trial; MECKI, Metabolic exercise test data combined with cardiac and kidney indexes;
MUSIC, MUerte Subita en Insuficiencia Cardiaca study; SHFM, the Seattle Heart Failure Model.
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remains high. Around 50% of people diagnosed with HF
will die within 5 years.2 The two most common causes
of death in patients with HF are sudden cardiac death
(SCD) and progressive pump failure. SCD in HF patients
is usually caused by lethal arrhythmias such as ventricular
tachycardia or ventricular fibrillation, and is reported to
be responsible for ~50% of all cardiovascular death in HF
patients.3 4
The most effective strategy for prevention of SCD in
patients with HF is the implantable cardioverter-defibrillator (ICD), associated with 54% relative risk reduction in
primary prevention,5 and 50% relative risk reduction in
arrhythmia-related death in secondary prevention.6 There
is a higher risk of SCD in patients with left ventricular
ejection fraction (LVEF) ≤35% than with LVEF >35%.7
At present, LVEF ≤35% is the major ICD indication for
primary prevention of SCD.8 However, real-world data
show that only 3%–5% of ICD patients for primary prevention with LVEF ≤35% receive shock therapies on an annual
basis,9 whereas some SCD victims have LVEF >35%.10 11
Identifying the patients who will be most likely to benefit
from primary prevention ICD is urgently needed. Based
on the latest literature, LVEF ≤35% is still an independent predictor of all-cause and cardiovascular mortality
in chronic systolic HF, and displays a better combination
of sensitivity and specificity than 40% cut-off.12 Finding
ways to evaluate the SCD risk in patients with lower EF
will be more efficient and economically significant.

Open access

Figure 1 Flow diagram of progress. HF, heart failure; LVEF,
left ventricular ejection fraction.

ventricular arrhythmias, and have been recommended to
predict the SCD in patients with HF. Although these new
methods are effective and non-invasive, the widespread
use in large HF population to predict SCD is difficult, due
to high equipment and technical requirements. Resting
12-lead ECG and Holter, as the longest surviving, broadly
available, quickly deployed and inexpensive tests, can
provide a measure of cumulative electrical risk, which
may be combined with other factors to improve the SCD
risk prediction.30
Based on above reasons, the novel risk assessment
tools should meet the following requirements: (1) the
risk model should be developed from the population
with low LVEF (≤35%) to accelerate its clinical application and promote the accuracy of ICD indications for
primary prevention. (2) More cardiac and non-cardiac
factors beyond LVEF should be included. (3) Electrical
risk factors should be included as candidate predictors
to evaluate the risk of sudden arrhythmic death. (4)
Although sometimes it is not easy to determine the cause
of death, SCD as the primary endpoint should be defined
whenever possible.
Data processing is the crucial step to develop the prognostic models. This study involves non-linear prediction
models, a large number of patients and numerous predictors with complicated correlations. Traditional hypothesis-driven statistical analysis is difficult to overcome these
challenges. The machine learning (ML) approaches have
great potential to improve the solution. They employ
computer algorithms to identify patterns in large datasets
with a large number of variables, analyse rules automatically and build both linear and non-linear models in order
to make data-driven predictions or decisions.31 Weng et
al32 found that ML significantly improved the accuracy
of cardiovascular risk prediction, increased the number
of patients who could benefit from preventive treatment
and avoided unnecessary treatment. Recent studies have
shown that the application of ML techniques may have
the potential to improve HF outcomes and management,
including cost savings by improving existing diagnostic
and treatment support systems.33 ML algorithms also have
been applied to predict SCD in some recent studies and
Meng F, et al. BMJ Open 2019;9:e023724. doi:10.1136/bmjopen-2018-023724

Aims
The purpose of our study is to develop and validate
new models to improve the prediction of SCD in HF
patients with low LVEF. The new strategies of identifying
HF patients most likely to benefit from primary prevention ICD will improve the revolution of ICD indications.
The specific research objective is to develop prediction
models to evaluate prognosis and SCD risk, respectively,
by ML methods and traditional Cox proportional hazard
regression in HF patients with low LVEF (≤35%).

Methods and analysis
Study design
This study is a retroprospective, multicentre, non-interventional, observational clinical registry. The primary
sponsor is The First Affiliated Hospital of Nanjing
Medical University. The study will be conducted
across 14 cardiovascular departments in tertiary A
hospitals throughout the People's Republic of China
(see online supplementary file 1).
The cases from January 2016 to December 2017 in the
First Affiliated Hospital of Nanjing Medical University
and Xiamen Cardiovascular Hospital Xiamen University will be collected retrospectively and followed-up
prospectively. About 500 retrospective cases meet the
inclusion criteria according to preliminary estimation.
The prospective recruitment has started in the above
14 hospitals since January 2018. The retrospective
cases and the first 1000 prospective cases will be used
to develop the prediction models. And the next 1000
prospective cases will be used for model validation. The
flow diagram of the progress is illustrated in figure 1.
Inclusion criteria
To participate in this study, patients must comply with all
of the following.
1. Diagnosis of heart failure with reduced EF (HFrEF)
according to the 2016 European Society of Cardiology
(ESC) HF guideline.8
2. LVEF ≤35% (measured by Simpson’s methods) after
optimised medication including ACEI or ARB, beta-blocker and MRA if available and not contraindicated at least 3 months.
3. Signed informed consent.
Exclusion criteria
The patient with any of the following will be excluded.
1. Hypertrophic cardiomyopathy.
2. Rheumatic heart disease.
3
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results indicate their significant advantages for predicting
SCD.34 35 However, more studies based on large-scale
cohort are needed to evaluate ML for prediction of SCD
in HF patients. Therefore, the application of ML for the
prediction of SCD in HF patients with low LVEF is technically innovative and clinically significant.

Open access

7.
8.
9.
10.
11.
12.
13.

Congenital heart disease.
Pulmonary heart disease.
Pericardial diseases and myocarditis.
Acute myocardial infarction in recent 3 months, including ST segment elevated myocardio infarction
(STEMI) and NSTEMI.
Aortic dissection.
Severe haematological disease including leukaemia,
lymphoma, aplastic anaemia.
Autoimmune disease.
Malignant tumour.
Hormone replacement.
Application of other interventional clinical trials.
Non-drug therapies for improving heart function:
cardiac resynchronization therapy with or without implantable cardioverter-defibrillator (CRT-P/D), ICD,
heart transplantation, surgical resection of ventricular aneurysm, interventional left ventricular restoration with Revivent/Parachute system), MitraClip
therapy for recurrent mitral regurgitation.

Endpoints
Primary endpoint
All-cause death and SCD, including cardiac death and
death from other causes.
Secondary endpoint
Lethal arrhythmia, sudden cardiac arrest, cardiopulmonary resuscitation, rehospitalisation due to HF.
Recruitment and consent
Participants will be identified and recruited at each of
the participating centres. The clinical status of potential
participants will be assessed, and their medical records
will also be reviewed to confirm the eligibility according
to the inclusion and exclusion criteria.

The study details will be explained to all potentially
eligible and interesting subjects. The patients who agree
to attend this study will sign the informed consent form
(ICF) indicating that they fully understand the study
and their rights of confidentiality and withdrawal from
the study without giving a reason.
Baseline evaluation
Prognostic models of HF in the last 10 years have
been reviewed, and the associated risk factors have
been ranked according to their corresponding HR
in respective risk models (table 1, figure 2). Age, sex,
New York Heart Association (NYHA) class, LVEF, prior
HF hospitalisation, course of HF, severe valvular heart
disease, atrial fibrillation, prior myocardial infarction/
coronary artery bypass grafting (CABG), renal dysfunction, chronic obstructive pulmonary disease (COPD),
diabetes mellitus (DM), ischaemic aetiology, decreased
systolic pressure, low body mass index, anaemia, hyponatremia, high N-terminal probrain natriuretic peptide
(NT-proBNP), uricemia and current smoker were
included. Variables which were not listed in previous
models but appear relevant to higher risk of SCD in
HF patients, and would therefore, merit consideration,
including syncope or presyncope, frequent premature
ventricular beat, non-sustained ventricular tachycardia,
complete left bundle branch block, long QT interval
and increased QT dispersion. In addition, self-care
ability, social support and psychological state including
depression and anxiety, are also predictors for subsequent poor prognosis in HF patients. The above risk
factors have been assessed and confirmed by an expert
panel of cardiologists and statisticians and will be
collected in this study particularly.

Figure 2 HR of variables in different risk models. Af, atrial fibrillation; BMI, body mass index; BNP, brain natriuretic
peptide; CABGB, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HR,
heart rate; ICM, ischaemic cardiomyopathy; MI, myocardial infarction; NYHA, New York Heart Association; SBP, systolic blood
pressure; VHD, valvular heart disease.
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Baseline
Data collection

Retrospective cases Prospective cases Regular visit

Informed consent
Quantification verification
(inclusion and exclusion)

√
√

√
√

Baseline evaluation

√

√

Medication

√

√

Questionnaires
9-EHFScBS
SSRS
HAMD
HAMA socioeconomic and educational status

Withdraw/death

√

Regular follow-up visit
(every 3 months)

√

Survival state

√

Adverse event

Once happen √

Study bias

Once happen √

Withdraw from the study
Death

Once happen √
Once happen √

√

√

9-EHFScBS, 9-item European Heart Failure Self-care Behaviour Scale; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale;
SSRS, Social Support Rating Scale.

The baseline data that will be collected in all eligible
subjects are as follows.
►► Demographic characteristics: date of birth, gender,
height and weight.
►► Lifestyle behaviour: smoking and drinking status.
►► Vital signs: blood pressure and heart rate.
►► NYHA class.
►► Aetiology of HF: the ischaemic aetiology will be
confirmed if any following point is met: (a) prior
myocardial infarction or revascularisation history
(CABG/percutaneous coronary intervention); (b)
left main or proximal segment of the left anterior
descending artery stenosis ≥75% showed by coronary
angiogram (CAG); (c) at least two main coronary
artery branches stenosis ≥75% showed by CAG. Otherwise, non-ischaemic HF should be identified.
►► Prior HF hospitalisation history: first HF hospitalisation or not, times of prior HF hospitalisation, the
course of HF (since the HF symptoms appear; if
unavailable, since the decreased EF was found).
►► Coronary heart disease history: myocardial infarction or angina history, CAG result, revascularisation
history, recent angina.
►► Arrhythmia history: atrial fibrillation, atrial flutter,
premature atrial contraction (PAC), premature
ventricular contraction (PVC), non-sustained VT
(NSVT), sustained VT, ventricular fibrillation and
some bradyarrhythmias.
►► Syncope or presyncope history.
►► Cardiac arrest/cardiopulmonary resuscitation history.
►► Other histories: hypertension, DM, COPD.
Meng F, et al. BMJ Open 2019;9:e023724. doi:10.1136/bmjopen-2018-023724

►►

►►

►►

►►

►►

►►

►►

Echocardiography: LV end-diastolic volume, LV
end-systolic volume and LVEF measured by Simpson’s
method; left atrial diameter, LV end-diastolic diameter and LV end-systolic diameter, pulmonary artery
systolic pressure. The status of valve regurgitation will
be evaluated (0-none; 1-mild; 2-mild to moderate;
3-moderate; 4-severe).
ECG: left/right bundle branch block will be recorded.
QRS duration and QT interval will be tested, and QT
dispersion will be calculated.
Holter: total heartbeat of the whole day, minimum/
maximum/ average HR, onset of PVC, PAC, NSVT,
VT, atrial fibrillation/flutter.
Laboratory tests results: serum creatinine, blood urea
nitrogen, serum natrium, haemoglobin, thyroid-stimulating hormone, free triiodothyronine, free
thyroxine, NT-proBNP.
Medication: ACEI/ARB, beta-blocker, aldosterone
antagonist, diuretic, digoxin, antiplatelet agent,
anticoagulant, statin, calcium channel blocker, antiarrhythmics, Ivabradine and angiotensin receptor
blocker-neprilysin inhibitor.
Evaluation of self-care behaviour and social support:
9-item European Heart Failure Self-care Behaviour
Scale (9-EHFScBS)36 will be used to determine the
self-care levels in HF patients. Social Support Rating
Scale (SSRS)37 will be used to evaluate the social
support condition in HF patients.
Assessment of psychological status: Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale
(HAMA).
5
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Table 2 The checklist for data collection
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►►

Socioeconomic and educational status: marital status,
educational status, monthly income, sources of
medical expenses, medical insurance.

Patient visits
After being enrolled in this research, all the subjects will
be followed-up periodically in the outpatient department
or by telephone interview every 3 months. The compliance with medications will be evaluated. As the primary
endpoint, all-cause death and SCD will be focused. Cause
6

of death will be analysed in detail. SCD is defined by the
WHO as unexpected death that occurs within 1 hour
from the onset of new or worsening symptoms (witnessed
arrest) or, if unwitnessed, within 24 hours from when
the individual was last observed alive and asymptomatic.38 The lethal arrhythmia including ventricular tachycardia/ ventricular fibrillation (VT/VF), sudden cardiac
arrest, cardiopulmonary resuscitation and rehospitalisation due to HF will be recorded carefully.
Meng F, et al. BMJ Open 2019;9:e023724. doi:10.1136/bmjopen-2018-023724
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Figure 3 Study framework and process. HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; SCD, sudden cardiac death.
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Data collection
In the prospective part, clinical data of subjects will be
collected and filled in the electrical data capture (EDC)
system at baseline and particular follow-up visit. In the
retrospective part, the same baseline information, except
for 9-EHFScBS, SSRS, HAMD and HAMA questionnaires,
will also be captured and input into the EDC system.
The following prospective visits (every 3 months) will be
conducted regularly and will be recorded in the EDC
system. Investigators will record all the information of
AEs, study bias, withdrawal from the study or death in
EDC system. In this study, the participants will be identified by study codes, and their names will not appear in
the EDC system. All the personal information including
contact information, medical record and outcome will not
be revealed to any person who has not been authorised by
a principal investigator. Professional staffs are responsible
for database management, data maintenance and regular
data backup. Data quality will be monitored regularly.
The data collection checklist is showed in table 2.
Data preprocessing
All above-collected variables, which might be predictors
of all adverse prognosis of HF described in endpoint
events, will be classified as uncontrollable variables (eg,
age, gender, history), controllable variables associated
with heart (eg, NYHA class, LVEF, increased heart rate)
and controllable variables beyond heart (eg, smoking,
anaemia, DM). Appropriate dummy variables will be
used for binary variables and categorical variables, and
quantitative variables will be fitted as a single continuous
measurement (eg, age, heart rate, NT-proBNP), unless
there is clear evidence of non-linearity. In order to create
a practice simple risk score, some continuous variables
will also be categorised into several groups according to
both common clinical cut points and expert advice.
Machine learning
Variable selection is the process of selecting a subset of
relevant variables for use in model construction, which
can substantially reduce the abundant information and
decrease the number of variables that are input to the
prediction model. In this study, the technique named as
‘information gain ranking’ will be used to select appropriate variables. Information gain represents the effectiveness of a variable based on entropy, which characterises
Meng F, et al. BMJ Open 2019;9:e023724. doi:10.1136/bmjopen-2018-023724

the unpredictability of a system. The information gain of
a variable is evaluated as the entropy difference of the
system when including and excluding this variable. Then,
the variables whose information gain scores are less than
a threshold are considered to be insignificant and will be
excluded from the prediction.
Prediction models for SCD in HF patients will be developed by the following classification algorithms, respectively: decision trees, logistic regression, support vector
machine, random forest and artificial neural network.29
The performance and general error estimation of these
ML models will be assessed by 10-fold cross-validation.
The dataset will be randomly divided into 10 equal
folds. Ninefolds will be used as the training set with the
remaining onefold as the validation set. The validation
results from 10 repeats will be combined to provide a
measure of the overall performance. The prediction
models derived from the above classification algorithms
above will be evaluated based on the accuracy, sensitivities, specificities and the area under the receiver-operating characteristic (ROC) curve. Finally, clinical experts
and computer specialists will discuss and choose the best
model to predict the prognosis of SCD in HF patients
and then perform further validation with the prospective
dataset.
Cox proportional hazards regression
Univariable Cox proportional hazards modelling will be
used to identify strong independent baseline candidate
predictors for the primary and secondary outcomes. We
will use both forward and backward stepwise procedure to
derive the multivariable Cox proportional hazards model
with p<0.05 as the inclusion criterion. Every variable in
the model will be multiplied by its β-coefficient, and the
products will be summed to calculate the risk score. Risk
function will be used to estimate the level of risk. The
calculating formula is as follows.39
P=h (t j; X k)=h0 (t j) exp (SCORE)
SCORE=Xk ßk = ß0 +ß1×1 +ß2×2 +………ßp xp
Model validation
The dynamic prospective cases will be used for external
validation of the optimal ML and Coxproportional
hazards models. The validation will be performed using
the models to calculate the probability of the outcome of
interest occurring for each individual included in the validation sample when compared with the events actually
observed to occur in this sample. The discrimination of
each model will be estimated by ROC curve. The calibration of the models will be assessed by the Hosmer-Lemeshow goodness-of-fit test. The ML prediction model will
be compared with the Cox proportional hazards regression model.
Patient and public involvement
During the design of this study, a survey of patient
requirements, including communication needs, follow-up
frequency and visit cost, was conducted in population
7
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During follow-up, lethal arrhythmia will be recognised
more precisely for patients who receive ICD or cardiac
resynchronization therapy with implantable cardioverter-defibrillator (CRT/D) implantation, and will
be recorded as an adverse event (AE). The patients,
who receive CRT-P/D, heart transplantation, surgical
resection of a ventricular aneurysm, interventional left
ventricular restoration with Revivent/Parachute system,
MitraClip therapy for recurrent mitral regurgitation, or
some other non-drug therapy to improve heart function,
will be followed up as usual.

Open access

Study timeframe
The retrospective data collection in the two subcentres started in March 2017, and prospective enrolment
in all 14 subcentres has started in January 2018. The
follow-up period is scheduled to end in December 2019.
The major part of data analysis will be performed from
January to June 2020. The study framework and process is
summarised in figure 3.
Ethics and dissemination
All necessary information about this study will be disclosed
to the patients. Every subject will be asked to sign the ICF,
indicating that they fully understand the study and voluntarily participate in this study. All results of this study will
be published in international peer-reviewed journals and
presented at relevant conferences.
Discussion
The evaluation of SCD risk in HF patients is a problem
that urgently needed to be solved. The existing prediction strategies for the SCD risk in HF patients lack clinical practice value for various reasons. ICD indication
for primary prevention of SCD could be optimised by
identifying the high SCD risk patients in HF with low
LVEF (≤35%). It is of great practical value and economic
significance.
We reviewed some predictive studies of HF in the past
years and ranked the risk factors according to their corresponding HR, which have been included in our study as
candidate risk factors. Otherwise, some other variables
which appear relevant to risk of SCD in HF patients are
also collected. Therefore, the efficiency and practicality of
predictive model development has been highly improved.
This study is the first multicentre registry study in
China, aimed to investigate the feasibility and accuracy of
applying ML to predict SCD in HF patients with low LVEF.
A broad range of outcomes, including SCD, all-cause
death, lethal arrhythmia, sudden cardiac arrest, cardiopulmonary resuscitation and rehospitalisation due to HF,
will be evaluated in this study, and the corresponding
prognostic models will be developed. ML and the traditional multivariable Cox proportional hazards regression
model will be derived from the same database and will be
compared.
8

The limitations of this study are as follows: (1) HF
patients with LVEF >35% will not be included based on
the design of this study, which will restrict the application
of the results of this study to the HF with low LVEF. (2) It
might be difficult to determine the endpoint of this study
sometimes for some patients, when dealing with SCD,
lethal arrhythmia and sudden cardiac arrest, especially
when outside the hospital.
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of potential HF participants, which provided important
evidence for drawing up this study protocol to meet most
of the patients’ needs, build close contact with patients,
enhance the overall adherence and improve the accuracy
of endpoint event. This study is not a patient-led research,
and patients are not involved in the recruitment of the
study. The study results will be informed to the participants by phone at the end of this study. The alive patients
will be evaluated with the new prediction model, and the
ICD intervention will be recommended to the high SCD
risk patients.
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